Insiders were able to sell their shares for the first time on Tuesday. And their selling took a toll on Tilray's share price.
Growth but no growth? That's what Aurora Cannabis expects in one area critical for its future.
These are two exceptional Canadian marijuana stocks, but one of them gives investors a little more oomph.
It's not the low share price that makes these stocks attractive, it's their huge growth prospects.
Great yields. Great bargains. What more could you ask for?
Which stock wins in a matchup between a top Canadian marijuana producer and a big lawn and gardens supplier with a growing cannabis business?
The robotic surgical system's greatest strength might be its data-driven approach.
These 3 Stocks Trounced the Top Marijuana ETFs in 2018, and Here's Why They'll Do It Again This Year
Repeat performances could be in store for these big marijuana winners from last year.
Adding these biotech stocks to your portfolio could be a great New Year's resolution for aggressive investors.
This gene-editing biotech could boom or bust over the next decade. But one potential future seems much more likely.
These biotech stocks jumped 31% or more over the last few days. Can their momentum continue?
Soaring sales, musical chairs at the top, and more make the cannabis company's Q2 update a memorable one.
A big shareholder commits to holding on to its shares of the Canadian marijuana stock, calming investors' concerns about a big sell-off next week.
Concerned about biosimilar competition for the world's top-selling drug? AbbVie isn't.
Forget the biotech's stock performance last year. The future should provide a much better story.
Coverage initiation from a leading investment firm stirred investors' enthusiasm for the Canadian marijuana stock.
GW Pharma CEO Justin Gover gave reasons for optimism about Epidiolex at the J.P. Morgan Healthcare Conference.
CVS Health spent a fortune to buy Aetna. CEO Larry Merlo explained at the J.P. Morgan Healthcare Conference why it should pay off for investors.
Here's what investors should have paid attention to in Illumina CEO Francis deSouza's talk at the J.P. Morgan Healthcare Conference.
An influential analyst's Increased optimism boosted the Canadian marijuana stock.